Welcome to our dedicated page for Quest Diagnostics SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated (NYSE: DGX) files reports with the U.S. Securities and Exchange Commission that provide formal insight into its operations as a medical laboratories company focused on diagnostic testing and diagnostic information services. On this page, investors can review Quest Diagnostics’ SEC filings alongside AI-powered tools that help explain the content and context of these documents.
Quest Diagnostics uses current reports on Form 8-K to disclose material events such as quarterly financial results and investor presentations. For example, the company has filed 8-Ks to announce results for specific quarters and to furnish presentation materials used at the J.P. Morgan Healthcare Conference, covering topics such as strategy, performance and market developments. These filings give investors structured access to information that the company shares with the market.
In addition to 8-Ks, users can expect to find Quest Diagnostics’ periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain detailed discussions of business segments, risk factors and financial condition. While these specific forms are not reproduced in the provided data, they are standard components of a public company’s SEC reporting and are accessible through this filings page.
The platform enhances these documents with AI-generated summaries that highlight key points, helping users navigate complex language and lengthy sections. For instance, AI tools can surface main themes from a 10-K, summarize quarterly performance from a 10-Q or clarify the significance of information furnished in an 8-K. Real-time updates from the SEC’s EDGAR system ensure that new filings appear promptly.
Investors interested in governance, capital allocation and executive communications can use this page to monitor Quest Diagnostics’ regulatory disclosures, while AI assistance streamlines the process of reviewing and interpreting the company’s filings.
Quest Diagnostics reported strong 2025 results with net revenues of $11.04 billion, up 11.8% from 2024, and reported diluted EPS of $8.75, up 13.8%. Adjusted diluted EPS was $9.85, up 10.3%. Fourth quarter revenue rose 7.1% to $2.81 billion, with diluted EPS of $2.18 and adjusted diluted EPS of $2.42. Cash from operations for 2025 was $1.89 billion.
The company issued 2026 guidance for net revenues of $11.70–$11.82 billion, reported diluted EPS of $9.45–$9.65, and adjusted diluted EPS of $10.50–$10.70. The Board raised the quarterly dividend 7.5% from $0.80 to $0.86 per share, or $3.44 annually, and expanded the share repurchase authorization by $1 billion, on top of approximately $0.4 billion remaining as of December 31, 2025.
Quest Diagnostics Incorporated is sharing an investor presentation about its strategy, business performance, and current market trends at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The slide deck used for this presentation is furnished as Exhibit 99.1 and contains the information discussed during the session.
The company notes that the materials may include forward-looking statements about its future results, which involve risks and uncertainties such as economic conditions, government investigations or lawsuits, competition, reimbursement complexity, regulatory changes, and acquisition activity. These risks are described in more detail in its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
Quest Diagnostics CEO and President James E. Davis reported an option exercise and related stock sales. On 11/25/2025, he exercised a non-qualified stock option to buy 55,093 shares of common stock at an exercise price of
That same day, he sold shares in several market transactions under a pre-arranged Rule 10b5-1 sales plan. These sales included 9,342 shares at a weighted average price of
Quest Diagnostics director reports small stock sale
A director of Quest Diagnostics Inc. reported selling 1,250 shares of common stock on 11/25/2025 at a price of $191.76 per share. This insider now directly owns 17,037 Quest Diagnostics shares after the transaction. The filing is a Form 4 submitted for board member Vicky B. Gregg, with the form signed by an attorney-in-fact.
Quest Diagnostics (DGX)
The filing states that 111,242,362 common shares are outstanding. The seller acquired the 55,093 shares as common stock on 11/25/2025, originating from an option granted on 02/21/2017 and paid for in cash.
Quest Diagnostics (DGX)1,250 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of
The shares to be sold were acquired from the issuer through restricted stock vesting on several dates in
Quest Diagnostics senior executive Mark E. Delaney, SVP & Chief Commercial Officer, reported stock option exercises and a share sale in Quest Diagnostics Inc. common stock. On 11/18/2025, he exercised 7,846 stock options at an exercise price of
Quest Diagnostics (DGX) reported a planned sale of common stock under Rule 144. The notice covers the potential sale of 7,946 common shares through Fidelity Brokerage Services on the NYSE, with an indicated aggregate market value of $1,488,683.10. These shares were acquired on 11/18/2025 by exercising stock options originally granted on 03/21/2022 (7,846 shares) and 02/23/2023 (100 shares), with payment made in cash. The filing notes that there were 111,242,362 common shares outstanding at the time referenced, giving investors context for the relative size of this planned sale.
Quest Diagnostics (DGX) CEO and President James E. Davis reported a disposition of common stock tied to equity compensation. On 11/05/2025, 7,143 shares were withheld and delivered to the issuer at $175.57 per share (Code F) to cover tax obligations arising from the vesting of restricted stock units. Following this tax withholding, Davis directly beneficially owned 120,480 shares.
Quest Diagnostics (DGX) disclosed an insider transaction by its Executive Vice President & CFO. On 10/21/2025, the officer acquired 68 shares of common stock at a price of $189.081 per share, reported as an acquisition through a dividend reinvestment plan. Following this transaction, the officer directly beneficially owns 25,741 shares. The filing also notes that dividend reinvestment plan shares are eligible for deferred reporting on Form 5 under Rule 16a-6, but the officer elected to report early on this Form 4.